Kiu Tay-Teo

Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis

Swathi Iyengar, Kiu Tay-Teo, Sabine Vogler et al. · PLoS Medicine · 2016 · 246 citations · Full text

Social Sciences, Economics, Pharmacoeconomics +17

Assistive technology policy: a position paper from the first global research, innovation, and education on assistive technology (GREAT) summit

Malcolm MacLachlan, David Banes, Diane Bell et al. · Disability and Rehabilitation Assistive Technology · 2018 · 181 citations · Full text

Public Affairs, Health Policy, Social Policy +16

Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies

Kiu Tay-Teo, André Ilbawi, Suzanne Hill · JAMA Network Open · 2019 · 91 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacology +16

Economic Evaluation alongside a Phase II, Multi-Centre, Randomised Controlled Trial of Very Early Rehabilitation after Stroke (AVERT)

Kiu Tay-Teo, Marj Moodie, Julie Bernhardt et al. · Cerebrovascular Diseases · 2008 · 76 citations

Health Professions, Pharmacoeconomics, Rehabilitation Medicine +17

Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer

Kiu Tay-Teo, Dario Trapani, Manju Sengar et al. · EClinicalMedicine · 2025 · 11 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17